Natixis’s BridgeBio Pharma BBIO Stock Holding History

Natixis’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-879	Closed	-$65.3K	–	1178
2026 Q1	$65.3K	Buy	+879	New	+$63.7K	﹤0.01%	969
2025 Q4	–	Sell	-73,342	Closed	-$3.81M	–	1133
2025 Q3	$3.81M	Buy	73,342 +73,322	+366,610%	+$3.58M	0.02%	481
2025 Q2	$864	Buy	+20	New	+$727	﹤0.01%	995
2025 Q1	–	Sell	-18,500	Closed	-$508K	–	987
2024 Q4	$508K	Hold	18,500	–	–	﹤0.01%	707
2024 Q3	$471K	Buy	+18,500	New	+$486K	﹤0.01%	650
2023 Q4	–	Sell	-31,800	Closed	-$839K	–	1046
2023 Q3	$839K	Buy	31,800 +25,800	+430%	+$732K	0.01%	529
2023 Q2	$103K	Sell	6,000 -9,000	-60%	-$135K	﹤0.01%	796
2023 Q1	$249K	Buy	+15,000	New	+$175K	﹤0.01%	724
2021 Q4	–	Sell	-29,375	Closed	-$1.38M	–	1231
2021 Q3	$1.38M	Buy	29,375 +23,725	+420%	+$1.27M	﹤0.01%	806
2021 Q2	$344K	Buy	5,650 +1,250	+28%	+$71.4K	﹤0.01%	771
2021 Q1	$271K	Buy	+4,400	New	+$288K	﹤0.01%	1006

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Natixis's BBIO Position: Q2 2026 in Review

Natixis sold out of BridgeBio Pharma (BBIO) in Q2 2026, closing a stake of 879 shares — an estimated $65.3K sold.

Natixis first reported a position in BBIO in Q1 2021 and held it in 11 quarters. The position peaked at $3.81M in Q3 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Natixis reported no remaining BridgeBio Pharma position as of Q2 2026 after selling out during the quarter.
Natixis sold 879 BridgeBio Pharma shares in Q2 2026, an estimated $65.3K.
Natixis first reported a position in BridgeBio Pharma in Q1 2021 and held it in 11 quarters.
Natixis's BridgeBio Pharma position peaked at $3.81M in Q3 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.